Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Ono Pharmaceutical

    - PMLiVE

    David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

    Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

    An estimated 2.4 million people globally are diagnosed with lung cancer each year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

    Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

    - PMLiVE

    Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

    More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

    ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

    - PMLiVE

    MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

    Approximately 43,000 people are diagnosed with lung cancer every year in the UK

    - PMLiVE

    Merck shares promising phase 3 results for Keytruda in ovarian cancer

    Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links